Urothelial Carcinoma: Muscle-Invasive and Metastatic Disease | MDedge Hematology and Oncology
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial) | BMC Cancer | Full Text
MVAC Chemotherapy Toxicity - Activity Seven:<br>Role of Neoadjuvant Chemotherapy in Bladder Cancer - Educational Centre:<br>Current Clinical Problems in Bladder Cancer
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ...
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ...
A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer - Clinical and Translational Radiation Oncology
Treatment Administration Schedule: Dose-Dense MVAC (every 14 days for... | Download Table
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial - Clinical Genitourinary Cancer
1438-Bladder/Urothelial neoadjuvant MVAC (methotrexate vinBLASTine DOXOrubicin ciSplatin) SUPERSEDED | eviQ
EAU15 - Poster: Neoadjuvant dose-dense MVAC for muscle invasive bladder cancer; efficacy and safety compared to the traditional MVAC regimen
1616-Bladder/Urothelial neoad ddMVAC (dd methotrexate vinBLASTine DOXOrubicin ciSplatin) | eviQ
Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience | PLOS ONE
Urothelial Carcinoma: Muscle-Invasive and Metastatic Disease | MDedge Hematology and Oncology
ESMO 2021: VESPER Trial Indicates Neoadjuvant Dose-Dense MVAC May be Practice-Impacting in Muscle Invasive Bladder Cancer. | PracticeUpdate
Randomized phase III trial of dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as perioperative chemotherapy for patients with MIBC. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints -
Dose-dense MVAC vs gemcitabine and cisplatin tied to better survival in bladder cancer patients | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Neoadjuvant Dose-Dense MVAC Demonstrates Superior Survival Outcomes in Bladder Cancer
Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cys
Bladder cancer
